uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume – What’s Next?

uniQure (NASDAQ:QURE) shares saw strong trading volume on Wednesday . 681,525 shares were traded during trading, a decline of 27% from the previous session’s volume of 930,653 shares.The stock last traded at $16.08 and had previously closed at $17.64.

Wall Street Analyst Weigh In

QURE has been the subject of a number of research analyst reports. Stifel Nicolaus upped their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Leerink Partners boosted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Cantor Fitzgerald lifted their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $33.88.

uniQure Stock Performance

The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $791.59 million, a price-to-earnings ratio of -3.27 and a beta of 0.41. The firm’s 50-day moving average price is $10.83 and its 200 day moving average price is $7.85.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. On average, sell-side analysts anticipate that uniQure will post -3.82 EPS for the current year.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Doheny Asset Management CA acquired a new stake in shares of uniQure in the 2nd quarter worth about $1,220,000. American Century Companies Inc. increased its holdings in uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares during the last quarter. Total Clarity Wealth Management Inc. purchased a new stake in shares of uniQure during the 2nd quarter worth approximately $74,000. Vanguard Personalized Indexing Management LLC raised its holdings in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the period. Finally, Marshall Wace LLP purchased a new position in uniQure in the second quarter valued at approximately $175,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.